Microbiology JC091: Fever After Chemotherapy: Infections In Immunocompromised Hosts Flashcards

1
Q

Chemotherapy on Rapidly dividing cells

A
  1. BM cells producing formed elements —> suppressed —> ***Pancytopenia
  2. Alimentary tract —> **Mucositis, Esophagitis, **Enterocolitis

Bacteria / Yeast in GI tract can go into submucosa / even into bloodstream + Neutrophils suppressed (∵ pancytopenia)
—> Bacteraemia / Fungaemia
—> High fever

Clinical picture: ***Neutropenic fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is fever

A

Definition:
- Oral temp >37.6oC >=once within a day
- **single oral temp >38.3oC / **sustained 38oC >1 hour

  • Often the only manifestation of infection in ***immunosuppressed host
  • Due to release of ***pro-inflammatory cytokines from endothelial cells / macrophages (IL1, TNF, IL4, 6)
  • Blunted by steroid, chemotherapy, NSAID
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

***Neutropenic fever

A

Absolute neutrophil count (ANC)
- **ANC <1.5: Neutropenia
- **
ANC <0.5: Severe neutropenia
- ANC <0.1: Profound neutropenia
—> lower ANC, longer duration —> higher susceptibility to infection

Post-chemotherapy neutropenia:
- Nadir: **7-14 days (∵ BM reserve of neutrophil)
- Duration: short to long (14-28 days)
- 14-28 days: **
Mucositis + **Low neutrophil + **Catheter nutrition (portal of entry) + ***Pulmonary infiltrate (e.g. fungal spores)
—> Bacteraemia / Fungaemia
—> highest risk of neutropenic fever
- 100% of post-chemotherapy patients developed fever if neutropenic for 3 weeks

Neutrophil:
- ***Short t1/2 intravascular (deplete quickly)
- replaced by marrow reserve (Metamyelocyte —> Myelocyte —> Promyelocyte —> Myeloblast) (7 days)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Approach to management of Neutropenic fever

A
  1. Full history + P/E (**daily)
    - skin
    - **
    oral (mucositis)
    - **lung (↓ air entry, crepitations)
    - **
    abdomen (tenderness)
    - ***perianal (cellulitis, abscess)
    - Hickman exit
    - BM biopsy / aspiration site
    - nasal sinus (tenderness)
  2. Investigations
    - CBP, LRFT
    - **blood culture from central venous catheter if infected catheter suspected (through 2 different ports —> central venous catheter + peripheral venous puncture —> difference in **time to positivity of culture)
  3. ***Start empirical broad spectrum antibiotics (before culture results come back)
  4. ***CXR (low risk patients), CT lung (high risk / symptomatic)
  5. Abdomen CT scan
    - abdominal pain, tenderness, diarrhoea
  6. **Stool for **C. difficile cytotoxin + culture
    - for +ve diarrhoea
  7. Urine, Skin swab, Sputum, BAL for testing
    - only if positive symptoms / lesions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Compromised vs Immunocompromised host

A

Compromised:
- >=1 significant defects in body’s natural defence mechanisms (Innate/ Adaptive)
—> as a result of **underlying disease / **therapy
—> predispose host to severe **infections / **neoplasia
- e.g. leukaemia, lymphoma, organ / BM transplant, use of immunosuppressives e.g. steroid, anti-TNF as anti-inflammatory, severe burn, massive trauma, alcoholism, under-nutrition, IV drug use

Immunocompromised:
- defects in immune system (Innate / Adaptive)
- can be demonstrated by laboratory tests (e.g. **reversed T4/T8 ratio in AIDS, **hypogammaglobulinaemia with CLL)

3 sided interaction:
1. Microbes (virulence)
- highly virulent organisms: Rabies virus, Bacillus anthracis, Dimorphic fungi (severe infection regardless of hosts immunity)
- low virulent organisms: CMV, Bacillus cereus, Candida albicans (can cause infection in immunocompromised host)
2. Host defence mechanism
3. Therapeutic drugs + procedures (immunosuppression, antibiotics, indwelling catheter)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

***Classification of Immunocompromised hosts

A

Congenital immunodeficiency

Acquired immunodeficiency (more common)
- HIV
- Non-HIV
—> Transplantation —> **BM transplant (more severe) vs Solid organ transplant (less severe)
—> Non-transplantation
——> Malignancy —> **
Haematological (most severe e.g. leukaemia, MM, lymphoma (less severe)) vs Solid tumour (usually during late stage, sometimes immunosuppression is due to chemotherapy)
——> Non-malignancy —> Autoimmune disease (e.g. SLE), Chronic diseases (e.g. uraemia, cirrhosis, COPD), Splenectomy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

***Clinically important mechanisms predisposing compromised host to infections

A
  1. Neutropenia (***Granulocytopenia) + other neutrophil dysfunction
  2. Cellular immune (***Helper T lymphocyte related) dysfunction
  3. ***Humoral immune (B lymphocyte-Ab related) dysfunction
  4. ***Anatomic-barrier damage (involving mucosa / skin)
    - e.g. severe burn, massive trauma, chemotherapy, radiotherapy induced mucositis
  5. Medical procedures, Indwelling devices, ***Antimicrobial therapy (kill normal flora —> predispose to colonisation by dangerous hospital flora which are antimicrobial resistant)
  6. ***Obstruction of conducting systems draining from normally sterile anatomical site to a non-sterile site
    - e.g. urinary, respiratory (bronchogenic carcinoma partially obstructing a bronchus causing stasis of secretions —> pneumonia), biliary tree
  7. ***Central NS dysfunction
    - e.g. stroke —> loss of gag reflex / coughing in brainstem lesions —> aspiration + pneumonia
  8. ***Major organ dysfunction (e.g. cirrhosis, uraemia, heart failure, COPD, gastric hypochlorhydria)
  9. Thrombocytopenia
    - ∵ ↓ platelet function
  10. Undernutrition with weight <75% of ideal body weight
    - ↓ neutrophil + T cell function
  11. Fe deficiency
    - ↓ neutrophil + T cell function
    - Fe overload also predispose to Klebsiella, Yersinia enterocolitica, Salmonella, Rhizopus infections
  12. ***Complement deficiency (innate humoral dysfunction)
  13. ***AutoAb against cytokines (e.g. IFNγ)
  14. Therapies
    - Therapeutic Ab
    - **Biologics against cytokine, chemokine (e.g. Anti-TNF (Infliximab), Anti-IL2, Anti-IL6 receptor, Anti-IL12, IL23)
    - **
    Kinase inhibitor of JAK-STAT signaling pathway (Ruxolitinib, Tofacitinib)
    —> predispose to wide variety of microbial infections esp. intracellular pathogens related to T cell immunity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Recognition of immunocompromised states

A

Importance:
1. Spectrum of pathogens highly ***predictable from specific defect

  1. ***Unusual pathogens may be involved
    - ubiquitous organisms can become opportunistic pathogens (e.g. Aspergillus, Candida, Pneumocystis)
    - reactivation of latent organisms (e.g. Herpes virus, Toxoplasma, M. Tb)
  2. Infection can be **rapidly fatal
    - should have high index of suspicion, rapid + accurate microbiological diagnosis from relevant specimens —> **
    early + ***aggressive therapy
  3. Clinical presentation of illness tend to be **unusual + **non-specific + ***subtle
    - absence / marked blunting of characteristic inflammatory S/S (e.g. Leukocytosis, Pus formation, Meningeal signs)
    - unusual sites may be involved (e.g. perirectal cellulitis in neutropenic patients)
  4. ***Polymicrobial infections often present
    - esp. when immune defects multiple / severe (e.g. BM transplant patients)
  5. Patients carrying oncogenic virus may develop virus-associated cancer with prolonged immunosuppression
    - **EBV-related: Post-transplant lymphoproliferative diseases
    - **
    HHV8-related: Kaposi’s sarcoma
    - HPV-related: Anogenital cancers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Common pathogens causing serious infections in immunocompromised hosts

A

Neutropenia (neutrophil dysfunction):
1. Bacteria
- Gram +ve: **S. epidermidis, **S. aureus, Strept. viridans (esp. mitis), Enterococcus spp.
- Gram -ve: **E. coli, K. pneumoniae, **P. aeruginosa

  1. Yeast
    - ***Candida spp., Trichosporon spp. Torulopsis spp.
  2. Filamentous fungi
    - ***Aspergillus, Mucor, Fusarium

Cellular immune dysfunction (T helper cell):
1. Bacteria (intracellular bacteria that attack RES)
- Listeria monocytogenes, **Salmonella spp., **Tuberculous + ***NTM spp., Nocardia, Legionella, Rhodococcus, Burkholderia pseudomallei

  1. Fungi
    - Cryptococcus neoformans, **Pneumocystis jirovecii (carinii), **Penicillium marneffei, other Dimorphic fungi (Histoplasma, Coccidioides)
  2. Virus
    - **HSV, **VZV, CMV, EBV, HPV, Resp viruses
  3. Protozoa
    - ***Toxoplasma gondii, Cryptosporidium, Microsporidia, Cyclospora, Isospora
  4. Helminth (only extracellular pathogen)
    - Strongyloides stercoralis

Humoral immune dysfunction:
1. **Encapsulated Bacteria (cannot be recognised unless opsonised by Ab)
- **
Streptococcus pneumoniae, ***Haemophilus influenzae, Capnocytophaga canimorsus

  1. Protozoa
    - Babesia microti

NB: Immunocompromised host equally prone to community-acquired infections + greater severity:
- Giant cell pneumonitis by measles virus in leukaemic child
- RSV pneumonia + respiratory failure in BM transplant patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Neutropenia

A

Causes:
- **Leukaemia
- Aplastic anaemia
- **
Intensive therapy with cytotoxic / irradiation
- **BM transplantation
- **
Patients with neutrophil dysfunction due to genetic defects

Incidence + Severity of infection inversely proportional to ANC
- ANC <1500 / uL: Abnormal / Neutropenia
- ANC <500 / uL: Severe neutropenia —> Rate of infection ↑
- ANC <100 / uL: Profound neutropenia —> Bacteraemia

Neutropenic fever:
- single oral temp >38.3oC / sustained 38oC >1 hour in a patient with ANC <=500

Pathogenesis:
- also depends on presence of other predisposing factors e.g. mucositis, indwelling vascular catheter
- Chemotherapy-induced mucositis —> damage mucosa throughout GI tract —> allow bacterial / fungal translocation across mucosa —> endogenous bacterial / fungal flora seeds bloodstream (Bacteraemia) —> neutropenic fever

Common sites of infection:
- Periodontium
- **Oropharynx
- **
Lungs
- Distal esophagus
- **Colon
- **
Perianal area
- Skin

Causative organisms:
- ***Endogenous flora
- Transient flora acquired from hospital environment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cellular immune dysfunction

A

T lymphocyte quantitative / qualitative defect:
- **Hodgkin’s disease
- **
AIDS
- Childhood acute lymphocytic leukaemia (ALL)
- **Solid organ transplant
- Engrafted BM transplant recipients
- **
Steroid, Cyclosporin, cytotoxics treatment
- ***AutoAb against IFNγ

Pathogenesis:
- Failure of **Helper T cell to activate macrophage / monocytes to kill ingested **intracellular pathogens

Causative organisms:
- **Intracellular pathogens (except Strongyloides)
- common pathogens that cause significant but seldom life-threatening disease in immunocompetent host and become latent later (e.g. Herpes viruses, Toxoplasma gondii)
- specific organism may occur more frequently in particular groups of patients (e.g. **
Herpes zoster in patients with Hodgkin lymphoma after recent radiotherapy, ***Mycobacterium abscessus infection in patients with AutoAb against IFNγ)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Humoral immune dysfunction

A

Causes:
- **CLL
- **
Multiple myeloma
- ***Agammaglobulinaemia

Pathogenesis:
- ↓ **Opsonising Ab production / **Clearing of Immune complexes in MM, CLL, (splenectomised including **asplenia patients)
—> ↑ risk of sepsis from **
encapsulated organisms (e.g. Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Capnocytophaga canimorsus, Babesia spp.)

Causative organisms:
- ***Encapsulated organisms (e.g. Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Capnocytophaga canimorsus, Babesia spp.)
- Extracellular pathogens (e.g. Aspergillus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Complement deficiency

A

Deficiency of membrane attack complex —> predispose to recurrent disseminated infected by **N. gonorrhoea / **N. meningitidis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Splenectomy

A

Pathogenesis:
- Spleen is critical in clearing ***encapsulated bacteraemic organisms which an individual has no prior contact and is non-immune

Causative organism:
- Overwhelming sepsis due to **encapsulated organisms
—> S. pneumoniae, H. influenzae, N. meningitidis, Capnocytophaga, **
Babesia spp. more common in ***splenectomised children (occasionally adults)
- Others: Salmonella, Plasmodium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Medical procedures + Indwelling devices

A

Pathogenesis:
- Indwelling catheters, endoscopic / surgical procedures that disrupt / bypass mucosa / skin —> predispose patients to **various infections
- Difficult to eradicate without removal of device (∵ bacteria + associated glycocalyx from adherent bacterial **
biofilms on the devices)

  1. Implanted vascular catheters
    - exit site infection / tunnel infection / catheter related bacteraemia, fungaemia
    - S. epidermidis, S. aureus, Bacillus spp., Candida spp.
  2. Foley catheter
    - UTI
    - Aerobic Gram -ve bacilli, Enterococcus
  3. Endotracheal tube
    - Pneumonia, Sinusitis
    - Aerobic Gram -ve bacilli
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Effect of antimicrobial therapy on normal flora

A

Pathogenesis:
- Antibiotics can suppress relatively non-invasive normal flora (esp. **anaerobes which tend to resists colonisation by antibiotic-resistant hospital-acquired organisms e.g. P. aeruginosa, Corynebacterium jeikium, yeasts)
—> During hospitalisation
—> Inadvertently introduce bacteria into patient by hands of medical personnel + various diagnostic / therapeutic procedures e.g. endoscopy, surgery, nursing activities
—> **
Established coloniser can produce ***life-threatening infections (difficult to treat + require use of more toxic + expensive antibiotics)

17
Q

Management of infections in immunocompromised hosts

A
  1. Recognition of specific immune defects in host
  2. High index of suspicion about infections even symptom is ***minimal (e.g. low grade fever, mental dullness)
    - early imaging e.g. CT, PET/CT
  3. Appropriate clinical specimens (e.g. blood, BAL) sent for
    - Direct visualisation (e.g. Gram stain, ZN stain)
    - Ag detection (e.g. latex agglutination test for C. difficile, Cryptococcus neoformans)
    - Culture
  4. Close cooperation with clinical microbiology laboratory esp. when unusual pathogens suspected (e.g. pneumocystis, fungus, nocardia, legionella)
  5. **Early aggressive + empirical therapy
    - indicated in some patients before definitive culture results available (e.g. IV **
    imipenem in febrile neutropenic patients)
  6. Temporary replacement of deficient immune component
    - ***Buffy coat (neutrophil) transfusion to combat bacterial infection not responding to antibiotics in patients with persistent neutropenia
  7. ***Ex-vivo expanded T lymphocytes for adoptive transfer of virus-specific immunity
    - treat drug resistant viral infections / virus-induced neoplasia
    - EBV-related post-transplant lymphoproliferative disease, late antiviral-resistant CMV disease, disseminated adenoviral disease
    - same strategy can be used in prevention of such infections in high risk transplant patients
  8. Monitoring
    - maximal efficacy of antibiotics with minimal SE e.g. drug assays
  9. Immune Reconstitution Inflammatory Syndrome (IRIS)
    - Paradoxical deterioration with fever + new inflammatory focus / progression of preexisting inflammatory focus can happen in temporal relationship to the recovery immune defect e.g. recovery of CD4 count after antiretroviral treatment / recovery of ANC after chemotherapy (
    Myeloid reconstitution syndrome)
18
Q

Prevention of infections in immunocompromised host

A
  1. **No unnecessary invasive procedures / Antimicrobial therapy
    - prevent impairment of host’s defence / any disturbance of ecological balance of patient’s microbial flora
    - **
    shorter duration of Antimicrobial therapy if appropriate
  2. ***Potential / Established sources of infection should be sought + ideally treated before any immunosuppressive therapy is instituted
    - e.g. tooth decay, chronic sinusitis, asymptomatic bacteriuria, anal fissures, recurrent boils, ingrown toe nails, chronic Salmonella carriage
  3. ***Serological screening for latent infections in donor / recipient before transplantation (e.g. HSV, CMV, HIV, HBV, HCV, Toxoplasma)
  4. Specific preventive measures in particular groups of patients
19
Q
  1. Specific preventive measures in particular groups of patients
A
  1. Protective isolation + **low-microbe food
    - e.g. **
    HEPA filter in rooms of BM transplant patients to prevent aspergillosis
  2. Oral prophylactic antibiotics
    - e.g. **Fluoroquinolone / Septrin to suppress **aerobic bacteria while **sparing anaerobes
    - **
    Selective decontamination —> prevent overgrowth by other aerobic bacteria + yeasts
    - used in patients expected to have prolonged (>10 days) + profound neutropenic (<100) e.g. BM transplant patients
    - unfortunately ↑ antibiotics resistance has severity impair usefulness of this approach
  3. Prophylactic antimicrobial (when such infection is anticipated + life threatening)
    - **Aciclovir for HSV / VZV, **Ganciclovir for CMV, **Entecavir for HBV
    - **
    Fluconazole for Candida spp., **Voriconazole / Posaconazole for yeasts + moulds, **Septrin for pneumocystis jirovecii
    - ***Septrin for Toxoplasma gondii
  4. ***Active immunisation
    - Pneumococcal vaccine (conjugated) + Hib vaccine (conjugated) for patients (esp. children) with / before splenectomy
  5. Passive immunisation (***IVIG)
    - in patients with CLL / BM transplant patients with Agammaglobulinaemia
  6. Acceleration of recovery of immune system
    - use of ***G-CSF to speed up quantitative + functional recovery of these phagocytes
  7. Total parenteral nutrition
    - for patients with chemotherapy-induced severe mucositis to maintain nutritional status
  8. ***Ex-vivo expanded T lymphocytes for adoptive transfer of virus-specific immunity
    - prevent drug resistant viral infections / virus-induced neoplasia
    - EBV-related post-transplant lymphoproliferative disease, late antiviral-resistant CMV disease, disseminated adenoviral disease
20
Q

Microbial invasion + Host response

A
  1. Adherence to epithelium
    - **Skin: pH, osmotic pressure, normal flora, sIgA
    - **
    Mucosa: pH, bile, sIgA, normal flora, digestive enzymes, lysozyme, flushing / peristalsis, lactoferrin, peroxidase
  2. Local infection, penetration of epithelium
    - ***Complement: alternative (CRP, MBP) in interstitial fluid —> humoral arm of innate defence
  3. Local infection of tissues
    - ***Phagocytes: PMN, macrophages, Langerhans cells
    —> Exudation
    —> Local inflammatory response syndrome (LIRS) (紅腫痛熱)
  4. Lymphatic spread
    - **Cellular immunity: T cells: CTL, CMI
    - **
    Humoral immunity: B cells: IgM, IgG, IgA
    - ***NK cells
  5. Adaptive immunity
    - Bacteraemia
    —> **Acute phase response
    —> **
    Systemic inflammatory response syndrome (SIRS)